Frontier IP Group PLC (AIM:FIPP, OTC:FGPPF) noted that The Vaccine Group, one of its portfolio companies, has successfully completed an Anglo-Chinese project to develop a vaccine against the most common types of Streptococcus suis.
Frontier IP Group holds a 17% equity stake in The Vaccine Group (TVG), whose vaccine may remove the need for antibiotics that are shown to be less resistant to the disease.
TVG developed nine vaccine constructs, two of which have been screened, and one which has demonstrated more than 75% efficacy in rabbits.
The project was a collaboration with two Chinese academic institutions and commercial partner Pulike Biological Engineering Company.
Pulike has begun preparation to make the vaccine candidate at pilot scale to support further clinical development.
TVG received a £403,000 grant as part of a £1.45mln agreement provided by the UK Department of Health and Social Care (DHSC) through Innovate UK, and the Chinese Ministry of Science and Technology.
In a statement, Frontier IP chief exective Neil Cragg commented: "We are very pleased with the progress made by TVG and its herpesvirus-based vaccine technology- this project shows it has the potential to combat bacteria as well as viruses.
“We are looking forward to results of further developments of the company's other animal vaccine projects for Lassa fever, African Swine Fever, and Porcine Reproductive and Respiratory Syndrome, and a COVID-19 vaccine for use in humans."